Adagene, Inc. (ADAG)
3.26
+0.09
(+2.84%)
USD |
NASDAQ |
Sep 17, 10:16
Adagene Enterprise Value : 300.12M for Sept. 16, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 16, 2026 | 300.12M |
| September 15, 2026 | 286.70M |
| September 14, 2026 | 306.84M |
| September 11, 2026 | 315.57M |
| September 10, 2026 | 309.52M |
| September 09, 2026 | 306.84M |
| September 08, 2026 | 321.61M |
| September 04, 2026 | 327.65M |
| September 03, 2026 | 335.04M |
| September 02, 2026 | 335.04M |
| September 01, 2026 | 331.68M |
| August 31, 2026 | 322.95M |
| August 28, 2026 | 334.37M |
| August 27, 2026 | 349.14M |
| August 26, 2026 | 345.78M |
| August 25, 2026 | 343.77M |
| August 24, 2026 | 349.14M |
| August 21, 2026 | 357.20M |
| August 20, 2026 | 361.90M |
| August 19, 2026 | 363.91M |
| August 18, 2026 | 359.21M |
| August 17, 2026 | 344.44M |
| August 14, 2026 | 335.71M |
| August 13, 2026 | 337.05M |
| August 12, 2026 | 339.07M |
| Date | Value |
|---|---|
| August 11, 2026 | 348.47M |
| August 10, 2026 | 360.55M |
| August 07, 2026 | 363.24M |
| August 06, 2026 | 365.25M |
| August 05, 2026 | 371.30M |
| August 04, 2026 | 331.68M |
| August 03, 2026 | 331.01M |
| July 31, 2026 | 339.07M |
| July 30, 2026 | 337.72M |
| July 29, 2026 | 337.05M |
| July 28, 2026 | 337.72M |
| July 27, 2026 | 324.30M |
| July 24, 2026 | 302.14M |
| July 23, 2026 | 313.55M |
| July 22, 2026 | 327.65M |
| July 21, 2026 | 334.37M |
| July 20, 2026 | 330.34M |
| July 17, 2026 | 328.32M |
| July 16, 2026 | 327.65M |
| July 15, 2026 | 333.70M |
| July 14, 2026 | 329.67M |
| July 13, 2026 | 343.77M |
| July 10, 2026 | 351.82M |
| July 09, 2026 | 345.78M |
| July 08, 2026 | 344.44M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ascletis Pharma, Inc. | 996.16M |
| CStone Pharmaceuticals Co. Ltd. | 1.116B |
| RemeGen Co., Ltd. | 5.418B |
| InnoCare Pharma Ltd. | 1.833B |
| JW (Cayman) Therapeutics Co. Ltd. | -- |
Enterprise Value Related Metrics
| Earnings Yield | -11.58% |
| Normalized Earnings Yield | -11.23 |